21.06 15:00 | Press Release: Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting |
21.06 15:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting |
23.05 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease |
23.05 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -2- |
23.05 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease |
15.05 07:00 | Press Release: Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 |
15.05 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 |
08.05 07:00 | Press Release: Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 |
08.05 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 |
24.04 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates |
24.04 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -2- |
24.04 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -3- |
24.04 07:00 | Press Release: Vivoryon Therapeutics N.V. Reports -4- |
24.04 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates |
16.04 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 |
16.04 07:00 | Press Release: Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 |
15.03 07:00 | Press Release: Vivoryon Therapeutics N.V. Announces Changes to Board Composition |
15.03 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Announces Changes to Board Composition |
04.03 07:00 | Press Release: Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer's Disease |
04.03 07:00 | dpa-AFX: GNW-Adhoc: Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer's Disease |
|